scholarly journals Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation

2005 ◽  
Vol 11 (8) ◽  
pp. 571-575 ◽  
Author(s):  
Vincent T. Ho ◽  
Corey Cutler ◽  
Shelly Carter ◽  
Paul Martin ◽  
Roberta Adams ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Thrombotic Microangiopathy ◽  
Marrow Transplant ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplant

scholarly journals Establishment of the Brazilian Registry of Hematopoietic Stem Cell Transplantation, using the database the Center for International Blood and Marrow Transplant Research

JBMTCT ◽  
2021 ◽  
Vol 2 (2) ◽  
pp. p100
Author(s):  
Cinthya Corrêa Corrêa ◽  
Heliz Regina Alves Das Neves ◽  
Anderson João Simione ◽  
Bruna Letícia Da Silva Santos Geraldo ◽  
Marcelo Pasquini ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplant ◽  
National Database ◽  
Active Centers ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplant

The number of hematopoietic stem cell transplantation (HSCT) in Brazil is growing rapidly. To better understand the outcomes of HSCT in Brazil, strategies have been developed with the Center for International Blood and Marrow Transplant Research (CIBMTR), using its standardized registry structure and data sharing application. The methods adopted to establish the registry were through efforts to increase the Brazilian centers that report to CIBMTR included training courses for HSCT data managers, the officialization of a multicenter HSCT study using the CIBMTR structure and the partnership between Brazilian Society of Bone Marrow Transplantation (SBTMO) and the CIBMTR. Here we describe the history for establishing the HSCT Brazilian database using the CIBMTR back to center data and present the aggregated results since 2016. We found a significant increase in the numbers of active centers reporting to CIBMTR from 11 in 2016 to 21 in 2020 corresponding to higher numbers of transplants reported to the CIBMTR from 574 to 921 in that period. The model used to generate this national database was effective as it leverages existing infrastructure to assess the activity and outcomes of HSCT in Brazil.  

scholarly journals HEMATOPOIETIC STEM CELL TRANSPLANTATION IN EGYPT CHALLENGES AND SOLUTIONS

2020 ◽  
Vol 12 (1) ◽  
pp. e2020023
Author(s):  
Hossam Kamel Mahmoud ◽  
Gamaleldin Mohamed Fathy ◽  
Alaa Elhaddad ◽  
Omar Abdelrahman Fahmy ◽  
Mohamed Abdelmooti ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplant ◽  
Hematopoietic Stem ◽  
Hematological Disorders ◽  
Blood And Marrow Transplant ◽  
The Difference

Hematopoietic stem cell transplantation (HSCT) is now an established treatment modality with definitive indications for many hematological disorders. However, this line of treatment requires tremendous resources, and it becomes increasingly difficult for transplanters  practicing in the developing world to reconcile the difference between what is possible and what is available. On the basis of 30 years of experience and more than 4250 transplants , this article will focus on the challenges faced our HSCT program and how they were solved. The HSCT program in Egypt started in 1989 on a narrow scale and since that time we faced many challenges.In 1997, the transplant rate increased dramatically with the opening of  many HSCT units distributed allover Egypt. Our team is registered in the Center for International Blood and Marrow Transplant Research ,and the number of transplants performed till December 2019 exceeded 4000 cases (60% allogeneic and 40% autologous).

scholarly journals Challenges and strategies used to increase the report of Brazilian Hematopoietic Stem Cell Transplantation (HSCT) data to the Center for International Blood and Marrow Transplant Research (CIBMTR)

JBMTCT ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 46-52
Author(s):  
Cinthya Corrêa Da Silva ◽  
Heliz Regina Alves das Neves ◽  
Anderson João Simione ◽  
Bruna Letícia da Silva Santos Geraldo ◽  
Eliana Cristina Martins Miranda ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Online Teaching ◽  
Marrow Transplant ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplant

To increase the report of Brazilian hematopoietic stem cell transplantation (HSCT) data to the Center for International Blood and Marrow Transplant Research (CIBMTR), the Data Managers Working Group (GTGD) of the Brazilian Society of Bone Marrow Transplants (SBTMO), and the Sao Paulo State Bone Marrow Association (AMEO) developed several strategies since 2016: training data managers (GDs) in national and international HSCT meetings, the development of a free online teaching course (EAD) in Portuguese on Transplant Essential Data (TED), on­line and presential training course for new data managers offered by AMEO, the approval by the National Committee of Ethics in Research (CONEP) of a national multicenter protocol to formalize sharing data of Brazilian transplants with the CIBMTR, and the first multicenter eval­uation our HSCT results using the CIBMTR Data Back to Center. The contract between SBTMO and CIBMTR was signed in 2019 and GTGD of the SBTMO was officially created. These actions resulted in an increase from 24 to 41 transplant centers registered at the CIBMTR from 2016 to 2019. The process of increasing adherence and continuity of HSCT reports to the CIBMTR is complex and requires commitment of all professionals involved HSCT. The success of this process depends on education of the GD and the involvement of all HSCT directors.

A Randomized Trial of Two 2-Dose Influenza Vaccination Strategies for Patients Following Autologous Hematopoietic Stem Cell Transplantation

2020 ◽  
Author(s):  
Benjamin W Teh ◽  
Vivian K Y Leung ◽  
Francesca L Mordant ◽  
Sheena G Sullivan ◽  
Trish Joyce ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Influenza Vaccination ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Influenza B ◽  
High Dose ◽  
Hematopoietic Stem

Abstract Background Seroprotection and seroconversion rates are not well understood for 2-dose inactivated influenza vaccination (IIV) schedules in autologous hematopoietic stem cell transplantation (autoHCT) patients. Methods A randomized, single-blind, controlled trial of IIV in autoHCT patients in their first year post-transplant was conducted. Patients were randomized 1:1 to high-dose (HD) IIV followed by standard dose (SD) vaccine (HD-SD arm) or 2 SD vaccines (SD-SD arm) 4 weeks apart. Hemagglutination inhibition (HI) assay for IIV strains was performed at baseline, 1, 2, and 6 months post–first dose. Evaluable primary outcomes were seroprotection (HI titer ≥40) and seroconversion (4-fold titer increase) rates and secondary outcomes were geometric mean titers (GMTs), GMT ratios (GMRs), adverse events, influenza-like illness (ILI), and laboratory-confirmed influenza (LCI) rates and factors associated with seroconversion. Results Sixty-eight patients were enrolled (34/arm) with median age of 61.5 years, majority male (68%) with myeloma (68%). Median time from autoHCT to vaccination was 2.3 months. For HD-SD and SD-SD arms, percentages of patients achieving seroprotection were 75.8% and 79.4% for H1N1, 84.9% and 88.2% for H3N2 (all P > .05), and 78.8% and 97.1% for influenza-B/Yamagata (P = .03), respectively. Seroconversion rates, GMTs and GMRs, and number of ILI or LCIs were not significantly different between arms. Adverse event rates were similar. Receipt of concurrent cancer therapy was independently associated with higher odds of seroconversion (OR, 4.3; 95% CI, 1.2–14.9; P = .02). Conclusions High seroprotection and seroconversion rates against all influenza strains can be achieved with vaccination as early as 2 months post-autoHCT with either 2-dose vaccine schedules. Clinical Trials Registration Australian New Zealand Clinical Trials Registry: ACTRN12619000617167.

Sign in / Sign up

Export Citation Format

Share Document